Valneva's 15-minute chart shows KDJ Death Cross and Bearish Marubozu signals.

Valneva's 15-minute chart indicates a shift in momentum towards the downside, as evidenced by a KDJ Death Cross and a Bearish Marubozu pattern observed on August 27, 2025 at 12:15. This suggests that the stock price is poised for further decline, as sellers have taken control of the market. The bearish momentum is likely to persist.

Valneva SE (NASDAQ: VALN) has encountered a significant setback following the U.S. Food and Drug Administration (FDA) suspension of its chikungunya vaccine, IXCHIQ. The FDA's decision, announced on August 22, 2025, was based on reports of four serious adverse events, including three deaths, attributed to the vaccine. This suspension has led to a 21% drop in Valneva's stock price, erasing a substantial portion of the 51% gain it had achieved in the preceding 30 days [1].

Analysts at Jefferies have responded to this development by lowering their price target on Valneva's stock from $18.00 to $14.00 while maintaining a Buy rating. The current stock price stands at $9.13, reflecting a 166% year-to-date gain, despite being in overbought territory according to InvestingPro data [1].

Technical indicators also point towards a bearish trend. Valneva's 15-minute chart on August 27, 2025, at 12:15, shows a KDJ Death Cross and a Bearish Marubozu pattern, suggesting that the stock price is poised for further decline. This indicates that sellers have taken control of the market, and the bearish momentum is likely to persist [2].

Valneva's financial health remains 'Fair' according to InvestingPro analysis, with strong liquidity ratios despite current unprofitability. The company's focus is on its Lyme disease Phase III readout expected by the end of 2025, which could significantly impact the stock price, with a 75% probability of success [1].

In other recent developments, H.C. Wainwright has assumed coverage on Valneva with a Buy rating and a price target of $18.00, highlighting the co-development of VLA15, a Lyme disease vaccine in partnership with Pfizer, which is currently in Phase 3 trials. Pivotal data for VLA15 is expected by the end of 2025, with regulatory submissions anticipated in 2026 and a potential commercial launch in 2027 [1].

References:
[1] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311
[2] https://www.investing.com/news/analyst-ratings/jefferies-lowers-valneva-stock-price-target-to-14-on-fda-suspension-93CH-4209311